Yale spore grant in skin cancer funded by the National Cancer Institute

The National Cancer Institute has renewed its funding of the Yale spore in Skin Cancer grant for an additional 5 years, and a total of $11.5 million. The goals of the grant are to improve prevention, risk assessment, measures for diagnosis and prognosis, and therapies for patients with melanoma.

"We have seen exciting developments from the research funded through our spore in Skin Cancer over the last five years and are thrilled to be able to continue this important work with the help of the National Cancer Institute," said Thomas J. Lynch, Jr., MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven.

The Specialized Programs of Research Excellence (spore) in Skin Cancer grant supports multidisciplinary research that extends from the laboratory bench to cancer patients in need. Ruth Halaban, senior research scientist in the Department of Dermatology and Yale Cancer Center member, is the principal investigator of the multi-faceted project.

"The team of researchers working within the spore grant spans the basic science and clinical departments around Yale University. The outcomes will be a reflection of the wide range of expertise involved in this project and we hope this will lead to improved diagnosis and treatment of patients with melanoma," said Halaban.

The main goal of the spore is to reveal biomarkers and targets for therapy based on state-of-the-art information from Next-Generation (Next-Gen) DNA sequencing, genomics, and proteomics analyses. There are four primary projects within the spore to accomplish the team's research priorities, as well as Developmental Research and Career Development Programs, a Biospecimen Resource, and Bioinformatics/Biostatistics Cores that support the translational research needs of all investigators participating in the spore projects.

The spore includes investigators in Dermatology, Medical Oncology, Pharmacology, Pathology, Genetics, Immunobiology, Therapeutic Radiology, Surgery, Epidemiology and Public Health, Computational Biology, and Bioinformatics at Yale University.

Yale Cancer Center is one of a select network of 41 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Smilow Cancer Hospital at Yale New Haven and Yale School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.

Yale Cancer Center press release

Yale New Haven Hospital (YNHH), part of Yale New Haven Health, is a nationally recognized, 1,541-bed, not-for-profit hospital serving as the primary teaching hospital for the Yale School of Medicine (YSM). Founded as the fourth voluntary hospital in the U.S. in 1826, today, YNHH has two New Haven-based campuses, and also includes Yale New Haven Children's Hospital, Yale New Haven Psychiatric Hospital and Smilow Cancer Hospital. YNHH has received Magnet designation from the American Nurses Credentialing Center, the nation’s highest honor of nursing excellence. YNHH has a combined medical staff of about 4,500 university and community physicians practicing in more than 100 specialties. www.ynhh.org

Similar Articles

11/25/19

Smilow Cancer Hospital receives re-accreditation by the Commission on Cancer

New Haven, CT (Nov. 25, 2019) – The Commission on Cancer (CoC), a quality program of the American College of Surgeons (ACoS), has granted three-year accreditation with commendation to the cancer program at Smilow Cancer Hospital (SCH) at Yale New Haven.

10/29/19

Smilow Cancer Hospital Care Center opens at Westerly Hospital

Westerly, RI (October 29, 2019) – Westerly Hospital celebrated the opening of its new Smilow Cancer Hospital Care Center Monday, the second new unit to open at the hospital in as many months.